ArticleStem cells translational medicine2026
Reproductive tissue-derived stromal cells rescue fertility by coupling follicular activation with endometrial remodeling.
Article in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMesenchymal stromal cells (MSCs) of various origins promote regeneration through paracrine signaling, immune modulation, and angiogenesis support. Premature ovarian failure (POF) is an excellent model to study coordinated ovarian and uterine repair, as cytotoxic injury simultaneously depletes ovarian follicles and impairs uterine receptors, resulting in infertility.
methodsWe established a busulfan/cyclophosphamide (Bu/Cy) POF model and applied human MSCs derived from reproductive/perinatal tissues-endometrium (hEndSCs), menstrual blood (hMenSCs), placenta (hPSCs), or follicular fluid (hFFSCs)-to treat the condition. The primary endpoint was pregnancy rate; secondary endpoints included serum anti-Mullerian hormone (AMH) levels and ovarian/uterine molecular profiles (RT-qPCR panels; selected ovarian signaling proteins by Western blot).
resultsChemotherapy reduced fertility (0%) and AMH levels compared to healthy controls. MSC therapy restored fertility in 41%-75% of mice, with hEndSC and hMenSC achieving the highest pregnancy rates (both 75%) and the highest AMH recovery. In the ovary, MSC increased Amh, Gdf3, Gja1, Zp1, and, depending on the source, Fshr, with concomitant activation of PI3K/AKT/mTOR effectors (p-AKT, p-mTOR, p-GSK3β, p-PDK1). In the uterus, MSC increased the expression of Col1a1, Col3a1, Ctgf, Pcna, Ccnd1, and Ki67, consistent with extracellular matrix repair and proliferative renewal.
conclusionsThese data suggest that MSCs derived from reproductive tissues, particularly endometrial origin, may restore fertility in POI by linking follicular activation to endometrial remodeling and support the translational development of MSC therapies that address both follicular depletion and uterine competence in infertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.